Howard G. Birnbaum

Independent Consultant
Howard G. Birnbaum


Ph.D. and M.A., economics, Harvard University; B.A., economics, Miami University

Summary of Experience

Dr. Birnbaum joined Analysis Group in 1997 and was instrumental in establishing the national prominence of the firm’s Health Economics and Outcomes Research practice. Dr. Birnbaum retired in 2021 but remains an affiliate of Analysis Group. An applied microeconomist, he has conducted economic investigations regarding the real-world comparative effectiveness of new treatments; the direct and indirect costs of illness; and models regarding the budget impacts and societal costs of various pharmaceutical, device, and medical interventions. Recently, Dr. Birnbaum has focused on estimating health care costs associated with environmental events such as air pollution, and health care savings from reduced air pollution due to increased urban tree planting. He is an expert on the use of public and private payer claims databases and has used these and other data sources to conduct health economics and outcomes research for pharmaceutical and device manufacturers, managed care organizations, government agencies, and environmental organizations. Dr. Birnbaum has also provided expert testimony and litigation support in matters regarding Medicare, Medicaid, and private insurer reimbursement; managed care issues; comparative effectiveness; and allegations of off-label promotion of prescription drugs. He has been a discussant at the US Food and Drug Administration regarding post-marketing requirements for prescription opioid products. Dr. Birnbaum serves on the editorial board of PharmacoEconomics and Drugs – Real World Outcomes, and has published articles in many leading medical, health economics, and managed care journals.

AG Contacts

Paul E. Greenberg